

**PARTICULARS TO APPEAR ON THE OUTER PACKAGING**

**Tin containing radio-active kit (radiolabel in lead shielding and labeling substance)**

**1. NAME OF THE MEDICINAL PRODUCT**

Octreoscan  
111 MBq/mL  
Kit for radiopharmaceutical preparation  
<sup>111</sup>In-Pentetreotide

**2. STATEMENT OF ACTIVE SUBSTANCE(S)**

Vial A (DRN 4920/A = code on vial): Indium (<sup>111</sup>In) Chloride 111 MBq/ml (122 MBq/1.1ml) at ART  
Vial B: Pentetreotide 10 micrograms

**3. LIST OF EXCIPIENTS**

Vial A: Contains also: hydrochloric acid, water for injection and ferric chloride hexahydrate.  
Vial B: Contains also: sodium citrate dihydrate, citric acid monohydrate, inositol and gentisic acid.

**4. PHARMACEUTICAL FORM AND CONTENTS**

Kit for radiopharmaceutical preparation. The kit consists of two vials:  
Vial A: Radiopharmaceutical precursor  
Vial B: Powder for solution for injection

**5. METHOD AND ROUTE(S) OF ADMINISTRATION**

For intravenous use after reconstitution.  
Read the package leaflet before use.

**6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN**

Keep out of the sight and reach of children.

**7. OTHER SPECIAL WARNING(S), IF NECESSARY**

First use: [YYYY-MM-DD hh:mm] h CET

**8. EXPIRY DATE**

EXP [DD MMM YYYY]

After reconstitution and labeling: expiry 6 hours

**9. SPECIAL STORAGE CONDITIONS**

Before and after reconstitution store below 25°C.

**10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE**

Radioactive waste disposal should be in accordance with national regulations.

**11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER**

Curium Netherlands B.V.  
Westerduinweg 3  
1755 LE Petten  
The Netherlands

**12. MARKETING AUTHORISATION NUMBER(S)**

88/143/94-C

**13. BATCH NUMBER**

Lot [12345]

**14. GENERAL CLASSIFICATION FOR SUPPLY**

Medicinal product subject to medicinal prescription.

**15. INSTRUCTIONS ON USE**

The sterile needle included in the pack is to be used for the reconstitution.

**16. INFORMATION IN BRAILLE**

Nevyžaduje se - odůvodnění přijato.

*Exception request submitted as OCTREOSCAN is solely hospital product, thus including the product name on label in Braille may be omitted.*

**PARTICULARS TO APPEAR ON THE OUTER PACKAGING**

**Lead pot**

**1. NAME OF THE MEDICINAL PRODUCT**

Indium (<sup>111</sup>In) Chloride  
111 MBq/mL  
Radiopharmaceutical precursor  
(DRN 4920/A = code on vial)

**2. STATEMENT OF ACTIVE SUBSTANCE(S)**

Indium (<sup>111</sup>In) Chloride 111 MBq/mL (122 MBq/1.1mL) at ART

**3. LIST OF EXCIPIENTS**

Contains also: hydrochloric acid, water for injection and ferric chloride hexahydrate.

**4. PHARMACEUTICAL FORM AND CONTENTS**

Radiopharmaceutical precursor

**5. METHOD AND ROUTE(S) OF ADMINISTRATION**

For intravenous use after reconstitution.  
Read the package leaflet before use.

**6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN**

Keep out of the sight and reach of children.

**7. OTHER SPECIAL WARNING(S), IF NECESSARY**

First use: [YYYY-MM-DD hh:mm] h CET

**8. EXPIRY DATE**

EXP [DD MMM YYYY hh:mm] h CET  
After reconstitution and labeling: expiry 6 hours

**9. SPECIAL STORAGE CONDITIONS**

Before and after reconstitution store below 25°C.

**10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE**

Radioactive waste disposal should be in accordance with national regulations.

**11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER**

Curium Netherlands B.V.  
Westerduinweg 3, 1755 LE Petten,  
Netherlands

**12. MARKETING AUTHORISATION NUMBER(S)**

88/143/94-C

**13. BATCH NUMBER**

Lot [12345]

**14. GENERAL CLASSIFICATION FOR SUPPLY****15. INSTRUCTIONS ON USE**

The sterile needle included in the pack is to be used for the reconstitution.

**16. INFORMATION IN BRAILLE**

Nevyžaduje se - odůvodnění přijato.

*Exception request submitted as OCTREOSCAN is solely hospital product, thus including the product name on label in Braille may be omitted.*

**MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS**  
**In case of radiopharmaceuticals the vial should be labelled in accordance to the article 66(3) of Directive 2001/83.**

**Vial label: Vial A**

**1. NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION**

DRN 4920/A  
In-111I

**2. METHOD OF ADMINISTRATION**

**3. EXPIRY DATE**

EXP [DD MMM YY] h CET

**4. BATCH NUMBER**

Lot [00000/000]

**5. CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT**

122 MBq/1.1 mL (111 MBq/mL)  
[YYYY-MM-DD hh:mm] h CET

**6. OTHER**

Curium Netherlands B.V., Petten, NL



**MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS**

**Vial label: Vial B**

**1. NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION**

OctreoScan Vial B  
Powder for solution for injection

**2. METHOD OF ADMINISTRATION**

Intravenous use after labelling with Vial A

**3. EXPIRY DATE**

EXP [DD MMM YYYY]  
After reconstitution: expiry 6 Hours

**4. BATCH NUMBER**

Lot [000000]

**5. CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT**

Pentetreotide 10 micrograms

**6. OTHER**

Curium Netherlands B.V.